Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Liabilities (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Total Liabilities for 10 consecutive years, with $130.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 6.06% year-over-year to $130.1 million, compared with a TTM value of $130.1 million through Dec 2025, down 6.06%, and an annual FY2025 reading of $130.1 million, down 6.06% over the prior year.
  • Total Liabilities was $130.1 million for Q4 2025 at Zevra Therapeutics, down from $137.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $139.0 million in Q2 2025 and bottomed at $5.4 million in Q3 2021.
  • Average Total Liabilities over 5 years is $71.0 million, with a median of $59.4 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 92.59% in 2021, then surged 672.01% in 2022.
  • Year by year, Total Liabilities stood at $5.8 million in 2021, then soared by 590.71% to $40.2 million in 2022, then surged by 174.65% to $110.5 million in 2023, then increased by 25.35% to $138.5 million in 2024, then decreased by 6.06% to $130.1 million in 2025.
  • Business Quant data shows Total Liabilities for ZVRA at $130.1 million in Q4 2025, $137.0 million in Q3 2025, and $139.0 million in Q2 2025.